WCLC 2025: DLL3 Therapy Shows Promise in Relapsed SCLC
A first-in-human trial has demonstrated encouraging clinical activity and manageable safety for the DLL3-targeted antibody-drug conjugate SHR-4849 in patients with relapsed small cell lung cancer (SCLC).